Invitation to Asarina Pharma R&D Day 2020

Asarina Pharma invites institutional investors, financial analysts and media to join its R&D day, focused on the upcoming Study results in the company's lead indication PMDD.

Date: March 26, 2020

Time: 14.00-17.00, registration from 13.30

Location: Helio GT30, Grev Turegatan 30, Stockholm

With presentations from PMDD practitioners and patients, as well as Asarina Pharma’s leading researchers and managers, the day will give a broad picture of PMDD, what the most meaningful clinical effects for a treatment are, and how the company's upcoming Phase IIb data will be evaluated and presented.

Doctor Paula Briggs: Lead study investigator, Liverpool Woman’s Hospital, consultant in sexual and reproductive health.

Professor Torbjörn Bäckström: Founder and CSO Asarina Pharma, Professor Dept. Clinical Sciences, Obstetrics and Gynecology Umeå University. 

Karin Ekberg, PhD: Chief Operating Officer, Asarina Pharma. 

Paula ‘Fenjima’ Manrique: PMDD patient and advocate, writer, speaker, regular guest as Gaming Expert on Swedish TV4:s Nyhetsmorgon.

Doctor Peter Nordkild: CEO Asarina Pharma.

The event will also offer some insights into Asarina Pharma's other ongoing research into menstrual migraine and Tourette syndrome.

Please register for R&D Day at the following link: https://financialhearings.com/event/12602/register/live_event

We look forward to meeting you!

For further information, please contact:

Peter Nordkild, CEO, Asarina Pharma AB

Phone: +45 25 47 16 46

E-mail: peter.nordkild@asarinapharma.com

About Asarina Pharma

We are a Swedish biotech company developing Sepranolone, the world’s first dedicated treatment for premenstrual dysphoric disorder (PMDD) and other menstrual-related conditions. Our product pipeline is built on over 40 years’ research into menstrual-related disorders like PMDD and menstrual migraine. With our new family of GAMSA compounds (GABAA Modulating Steroid Antagonists), we aim to deliver a new generation of efficacious and safe drugs for still widely untreated conditions, thereby becoming a leading Women’s Health company.

Tags:

Subscribe

Documents & Links